Gilead Sciences Shares Outstanding 2010-2024 | GILD

Gilead Sciences shares outstanding for the quarter ending September 30, 2024 were 1.254B, a 0.24% decline year-over-year.

  • Gilead Sciences 2023 shares outstanding were 1.258B, a 0.32% decline from 2022.
  • Gilead Sciences 2022 shares outstanding were 1.262B, a 0% decline from 2021.
  • Gilead Sciences 2021 shares outstanding were 1.262B, a 0.08% decline from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Gilead Sciences Shares Outstanding 2010-2024 | GILD

  • Gilead Sciences 2023 shares outstanding were 1.258B, a 0.32% decline from 2022.
  • Gilead Sciences 2022 shares outstanding were 1.262B, a 0% decline from 2021.
  • Gilead Sciences 2021 shares outstanding were 1.262B, a 0.08% decline from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B
Legend Biotech (LEGN)$7.5B